Application of a novel targeting nanoparticle contrast agent combined with magnetic resonance imaging in the diagnosis of intraductal papillary mucinous neoplasm Retraction in /10.3892/etm.2024.12720

Sun,Min; Kang,Liqing; Cui,Yanchao; Li,Guoce

doi:10.3892/etm.2018.6349

Application of a novel targeting nanoparticle contrast agent combined with magnetic resonance imaging in the diagnosis of intraductal papillary mucinous neoplasm

Retraction in: /10.3892/etm.2024.12720

Authors:
- Min Sun
- Liqing Kang
- Yanchao Cui
- Guoce Li
View Affiliations

Affiliations: NMR Department, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China, Emergency Department, Beijing University of Chinese Medicine, The Third Affiliated Hospital, Beijing 100029, P.R. China
Published online on: June 22, 2018 https://doi.org/10.3892/etm.2018.6349
Pages: 1216-1224
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intraductal papillary mucinous neoplasm (IPMN) is a severe disease with macroscopic visible mucin secretion that primarily occurs in biliary tracts or pancreatic ducts. In comparison with standard diagnostic imaging, probing the molecular abnormalities associated with the initial stages of diseases rather than imaging the end effects markedly improves the accuracy of diagnosis. In the present study, magnetic resonance imaging (MRI) in combination with the contrast agent PEGylated magnetoliposome consisting of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd‑EOB‑DTPA) and target molecules of IPMN were investigated in the diagnosis of patients with suspected IPMN. The present investigation indicated that the novel targeting nanoparticle contrast agent targeted platelet‑derived growth factor receptor‑β and RET, and maintained a high affinity with tumor markers located on the IPMN surface. The novel targeting nanoparticle contrast agent combined with MRI exhibited increased sensitivity in diagnosing early‑stage patients with IPMN. Furthermore, image quality was improved following the use of the novel targeting nanoparticle contrast agent combined with MRI compared with standard MRI. The targeting nanoparticle contrast agent retained sufficient affinity and was present for an adequate amount of time to observe the tumor mass in papillae using MRI. Notably, the targeting nanoparticle contrast agent was metabolized at 12 h post‑injection. In conclusion, these outcomes indicate that the novel targeting nanoparticle contrast agent combined with MRI improved image quality and sensitivity compared with standard MRI, which suggests that this approach may be promising for clinical detection in patients with suspected IPMN.

View Figures

View References

1	Chick JF, Chen JX, Bennett SJ, Chauhan NR, Reddy SN, Gade T, Watts MM and Nadolski GJ: Incidental regression of a suspected pancreatic intraductal papillary mucinous neoplasm after nontarget embolization. J Vasc Interv Radiol. 27:922–923. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chang X, Li J, Jiang Y, Li Y, Lu Z and Chen J: Intraductal papillary mucinous neoplasm of pancreas: Analysis of the clinicopathologic features and prognosis. Zhonghua Bing Li Xue Za Zhi. 45:159–164. 2016.(In Chinese). PubMed/NCBI
3	Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, Al-Haddad MA, House MG, Zyromski NJ, Nakeeb A and Schmidt CM: Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease? Am J Surg. 211:512–518. 2016. View Article : Google Scholar : PubMed/NCBI
4	Suzuki Y, Nakazato T, Yokoyama M, Kogure M, Matsuki R, Abe N, Mori T, Ohkura Y and Sugiyama M: Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 45:1227–1232. 2016. View Article : Google Scholar : PubMed/NCBI
5	Vitali F, Strobel D, Pfeifer L, Heinrich M, Wachter D, Neurath MF and Wildner D: Neuroendocrine tumor of the pancreas with cystic appearance mimicking a progressive intraductal papillary mucinous neoplasm: Pitfall in medical imaging. Endoscopy. 48:E302–E303. 2016. View Article : Google Scholar : PubMed/NCBI
6	Trindade AJ, Sejpal DV and Sideridis K: Digital pancreatoscopy in the management of main duct intraductal papillary mucinous neoplasm. Gastrointest Endosc. 84:1060–1061. 2016. View Article : Google Scholar : PubMed/NCBI
7	Escalon JG, Gerst S, Porembka M, Allen PJ and Do RK: Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. Clin Imaging. 40:1195–1199. 2016. View Article : Google Scholar : PubMed/NCBI
8	Hong HS and Kim MJ: Diagnosis of pancreatic intraductal papillary mucinous neoplasm. Korean J Gastroenterol. 52:207–213. 2008.(In Korean). PubMed/NCBI
9	Tanaka M: Intraductal papillary mucinous neoplasm of the pancreas: Diagnosis and treatment. Pancreas. 28:282–288. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ebell MH, Culp MB and Radke TJ: A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
11	Mennella S, Paparo F, Revelli M, Baccini P, Secondini L, Barbagallo S, Friedman D and Garlaschi A: Magnetic resonance imaging of breast cancer: Does the time interval between biopsy and MRI influence MRI-pathology discordance in lesion sizing? Acta Radiol. 58:800–808. 2016. View Article : Google Scholar : PubMed/NCBI
12	Karahaliou A, Vassiou K, Arikidis NS, Skiadopoulos S, Kanavou T and Costaridou L: Assessing heterogeneity of lesion enhancement kinetics in dynamic contrast-enhanced MRI for breast cancer diagnosis. Br J Radiol. 83:296–309. 2010. View Article : Google Scholar : PubMed/NCBI
13	Franchini Comes M, Baldi G, Bonacchi D, Gentili D, Giudetti G, Lascialfari A, Corti M, Marmorato P, Ponti J, Micotti E, et al: Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: A potential theranostic approach against cancer. Small. 6:366–370. 2010. View Article : Google Scholar : PubMed/NCBI
14	Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW and Kim YT: Diagnosis and staging of primary ovarian cancer: Correlation between PET/CT, doppler US and CT or MRI. Gynecol Oncol. 116:389–394. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hong GS, Byun JH, Kim JH, Kim HJ, Lee SS, Hong SM and Lee MG: Thread sign in biliary intraductal papillary mucinous neoplasm: A novel specific finding for MRI. Eur Radiol. 26:3112–3120. 2016. View Article : Google Scholar : PubMed/NCBI
16	Mazzei MA, Guerrini S, Mazzei FG, Squitieri Cioffi N, Notaro D, de Donato G, Galzerano G, Sacco P, Setacci F, Volterrani L and Setacci C: Follow-up of endovascular aortic aneurysm repair: Preliminary validation of digital tomosynthesis and contrast enhanced ultrasound in detection of medium-to long-term complications. World J Radiol. 8:530–536. 2016. View Article : Google Scholar : PubMed/NCBI
17	Schalk S, Demi L, Bouhouch N, Kuenen MPJ, Postema AW, de la Rosette JJMCH, Wijkstra H, Tjalkens TJ and Mischi M: Contrast-enhanced ultrasound angiogenesis imaging by mutual information analysis for prostate cancer localization. IEEE Trans Biomed Eng. 64:661–670. 2017. View Article : Google Scholar : PubMed/NCBI
18	DiMaio CJ, Weis-Garcia F, Bagiella E, Tang LH and Allen PJ: Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm. Gastrointest Endosc. 83:1205–1209. 2016. View Article : Google Scholar : PubMed/NCBI
19	Iannicelli E, Carbonetti F, Di Pietropaolo M, Federici GF, Capurso G and David V: Magnetic resonance cholangiopancreatography with secretin stimulation in the diagnosis of intraductal papillary mucinous neoplasm: A paradigmatic case report. Case Rep Radiol. 2014:8203592014.PubMed/NCBI
20	Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O and Lang SA: Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis and metastasis by effects on tumor cells, endothelial cells and pericytes in pancreatic cancer. Mol Cancer Ther. 10:2157–2167. 2011. View Article : Google Scholar : PubMed/NCBI
21	Cavel O, Shomron O, Shabtay A, Vital J, Trejo-Leider L, Weizman N, Krelin Y, Fong Y, Wong RJ, Amit M and Gil Z: Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 72:5733–5743. 2012. View Article : Google Scholar : PubMed/NCBI
22	Liu H, Ma Q and Li J: High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem. 347:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
23	Donahue TR and Hines OJ: CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg. 33:710–715. 2009. View Article : Google Scholar : PubMed/NCBI
24	Mi P, Kokuryo D, Cabral H, Kumagai M, Nomoto T, Aoki I, Terada Y, Kishimura A, Nishiyama N and Kataoka K: Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Control Release. 174:63–71. 2014. View Article : Google Scholar : PubMed/NCBI
25	Liang M, Zhao J, Xie B, Li C, Yin X, Cheng L, Wang J and Zhang L: MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol. 85:546–552. 2016. View Article : Google Scholar : PubMed/NCBI
26	Stangenberg L, Shuja F, Carelsen B, Elenbaas T, Wyers MC and Schermerhorn ML: A novel tool for three-dimensional roadmapping reduces radiation exposure and contrast agent dose in complex endovascular interventions. J Vasc Surg. 62:448–455. 2015. View Article : Google Scholar : PubMed/NCBI
27	Sahibzada I, Batura D and Hellawell G: Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance. Int Urol Nephrol. 48:529–533. 2016. View Article : Google Scholar : PubMed/NCBI
28	Angelov KG, Vasileva MB, Grozdev KS, Sokolov MB and Todorov G: Clinical and pathological characteristics and prognostic factors for gastric cancer survival in 155 patients in Bulgaria. Hepatogastroenterology. 61:2421–2424. 2014.PubMed/NCBI
29	Frithiof H, Welinder C, Larsson AM, Rydén L and Aaltonen K: A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med. 13:1262015. View Article : Google Scholar : PubMed/NCBI
30	Katikireddy KR and O'Sullivan F: Immunohistochemical and immunofluorescence procedures for protein analysis. Methods Mol Biol. 784:155–167. 2011. View Article : Google Scholar : PubMed/NCBI
31	Feldman AT and Wolfe D: Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
32	Uedo N and Yao K: Endoluminal diagnosis of early gastric cancer and its precursors: Bridging the gap between endoscopy and pathology. Adv Exp Med Biol. 908:293–316. 2016. View Article : Google Scholar : PubMed/NCBI
33	Feliciano Cespedes EM, Kroenke CH, Bradshaw PT, Chen WY, Prado CM, Weltzien EK, Castillo AL and Caan BJ: Postdiagnosis weight change and survival following a diagnosis of early stage breast cancer. Cancer Epidemiol Biomarkers Prev. 26:44–50. 2016. View Article : Google Scholar : PubMed/NCBI
34	Tada M and Koike K: Pancreatic tumor: Progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN); 1. Symptoms and surveillance of IPMN and MCN. Nihon Naika Gakkai Zasshi. 101:51–56. 2012.(In Japanese). View Article : Google Scholar : PubMed/NCBI
35	Ji Y, Tan YS, Zhu XZ, Zeng HY, Kuang TT and Jin DY: Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas. Zhonghua Bing Li Xue Za Zhi. 35:77–81. 2006.PubMed/NCBI
36	Shah RB, Leandro G, Romerocaces G, Bentley J, Yoon J, Mendrinos S, Tadros Y, Tian W and Lash R: Improvement of diagnostic agreement among pathologists in resolving an ‘atypical glands suspicious for cancer’ diagnosis in prostate biopsies utilizing a novel ‘disease-focused diagnostic review’ quality improvement process. Hum Pathol. 56:155–162. 2016. View Article : Google Scholar : PubMed/NCBI
37	Haider MA, Yao X, Loblaw A and Finelli A: Multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A systematic review. Clin Oncol (R Coll Radiol). 28:550–567. 2016. View Article : Google Scholar : PubMed/NCBI
38	Ringold DA, Yen RD and Chen YK: Direct dorsal pancreatoscopy with narrow-band imaging for the diagnosis of intraductal papillary mucinous neoplasm and pancreas divisum (with video). Gastrointestinal Endosc. 72:1263–1264. 2010. View Article : Google Scholar
39	Thestrup KC, Logager V, Baslev I, Møller JM, Hansen RH and Thomsen HS: Biparametric versus multiparametric MRI in the diagnosis of prostate cancer. Acta Radiol Open. 5:20584601166630462016.PubMed/NCBI
40	Vargas HA, Schor-Bardach R, Long N, Kirzner AN, Cunningham JD, Goldman DA, Moskowitz CS, Sosa RE, Sala E, Panicek DM and Hricak H: Prostate cancer bone metastases on staging prostate MRI: Prevalence and clinical features associated with their diagnosis. Abdom Radiol (NY). 42:271–277. 2016. View Article : Google Scholar
41	Moore CM and Taneja SS: Integrating MRI for the diagnosis of prostate cancer. Curr Opin Urol. 26:466–471. 2016. View Article : Google Scholar : PubMed/NCBI
42	Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, et al: Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med. 68:261–271. 2012. View Article : Google Scholar : PubMed/NCBI
43	Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N and Mundhenke C: Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett. 273:70–79. 2009. View Article : Google Scholar : PubMed/NCBI
44	Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, et al: Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. Ann Oncol. 19:1713–1719. 2008. View Article : Google Scholar : PubMed/NCBI
45	Gehmert S, Prantl L, Vykoukal J, Alt E and Song YH: Breast cancer cells attract the migration of adipose tissue-derived stem cells via the PDGF-BB/PDGFR-beta signaling pathway. Biochem Biophys Res Commun. 398:601–605. 2010. View Article : Google Scholar : PubMed/NCBI
46	Zhang YY, Liu ZB, Ye XG and Ren WM: Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression. Mol Med Rep. 14:3941–3946. 2016. View Article : Google Scholar : PubMed/NCBI
47	Rotondi M, Coperchini F, Awwad O, Pignatti P, Di Buduo CA, Abbonante V, Magri F, Balduini A and Chiovato L: Effect of Interferon-γ on the Basal and the TNFα-stimulated secretion of CXCL8 in thyroid cancer cell lines bearing either the RET/PTC rearrangement or the BRAF V600e mutation. Mediators Inflamm. 2016:85124172016. View Article : Google Scholar : PubMed/NCBI
48	Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM and Morandi A: Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget. 7:80543–80553. 2016. View Article : Google Scholar : PubMed/NCBI
49	Baba T, Sakamoto Y, Kasamatsu A, Minakawa Y, Yokota S, Higo M, Yokoe H, Ogawara K, Shiiba M, Tanzawa H and Uzawa K: Persephin: A potential key component in human oral cancer progression through the RET receptor tyrosine kinase-mitogen-activated protein kinase signaling pathway. Mol Carcinog. 54:608–617. 2015. View Article : Google Scholar : PubMed/NCBI
50	Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, et al: Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: A multicenter retrospective study. J Gastroenterol. 51:144–152. 2016. View Article : Google Scholar : PubMed/NCBI